Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Tech IncfiledCriticalSiga Tech Inc
Publication of AR122178A2publicationCriticalpatent/AR122178A2/en
Una composición farmacéutica líquida que comprende 4-trifluorometil-N-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1H)-il)-benzamida (ST-246) en una concentración de 2 mg/ml a 20 mg/ml; hidroxipropil-b-ciclodextrina en una concentración de 125 mg/ml a 400 mg/ml; y agua.A liquid pharmaceutical composition comprising 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindole-2(1H )-yl)-benzamide (ST-246) in a concentration of 2 mg/ml to 20 mg/ml; hydroxypropyl-b-cyclodextrin in a concentration of 125 mg/ml to 400 mg/ml; and water.
ARP210101425A2010-08-052021-05-27
LIQUID PHARMACEUTICAL COMPOSITION AND PROCESS TO PREPARE IT
AR122178A2
(en)
DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORINE-N- (QUINUCLIDIN-3-IL) BENZO [B] THIOPHEN-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME
HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID
Pharmaceutical composition for injection that compensates for an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg / ml, the concentration of trometamol is between 1.8 and 5.8 mg / ml, and the pH is between 7.0 and 9.5; and its use for the treatment of pain, inflammation or fever.